Nimbus Therapeutics vs Profluent Bio
Nimbus Therapeutics vs Profluent Bio, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Nimbus Therapeutics is on 51/100 and Profluent Bio on 58/100.
Where each one leads
Nimbus Therapeutics
- agent readiness: 27/100 against 22/100
- domain rating: 55/100 against 40/100
- funding raised: $589M against $150M
Profluent Bio
- our overall score: 58/100 against 51/100
At a glance
| Measure | Nimbus Therapeutics | Profluent Bio |
|---|---|---|
| What it is | Nimbus Therapeutics is a clinical-stage biotech company using computational drug discovery to develop small molecule medicines. | AI-first company designing novel, functional proteins to revolutionize biomedicine and agriculture. |
| Category | Biotechnology, Drug Discovery, AI, Machine Learning | Biotech, Life Science, Artificial Intelligence, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Software |
| Founded | 2009 | 2022 |
| Headquarters | Boston, United States | Emeryville, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Nimbus Therapeutics | Profluent Bio |
|---|---|---|
| Employees | Not published | 66 |
| Open roles | Not published | 13 |
| Total funding | $589M | $150M |
| Latest round | Series F | Series A |
| LinkedIn followers | Not published | 11,880 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Nimbus Therapeutics | Profluent Bio |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 51/100 | 58/100 |
| Traction | 40/100 | Not published |
| Team | 30/100 | Not published |
| Community | 8/100 | Not published |
| Search visibility | 18/100 | 7/100 |
| Quality | 70/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | F (27/100) | F (22/100) |
| Domain ratingLink authority, 0-100 | 55/100 | 40/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Nimbus Therapeutics | Profluent Bio |
|---|---|---|
| Hosting | Google Cloud | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | WordPress | Webflow |
| Frameworks | Not detected | Tailwind CSS, Bootstrap |
| Analytics | Google Analytics 4, Segment, Microsoft Clarity | Google Analytics 4 |
Nimbus Therapeutics vs Profluent Bio: common questions
Which is better, Nimbus Therapeutics or Profluent Bio?
On our 0-100 score Profluent Bio rates higher (58/100 against 51/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.
How do Nimbus Therapeutics and Profluent Bio compare on the numbers?
Nimbus Therapeutics leads on agent readiness (27/100 against 22/100), domain rating (55/100 against 40/100), funding raised ($589M against $150M). Profluent Bio leads on our overall score (58/100 against 51/100).
Read the full Nimbus Therapeutics review and pricing or the Profluent Bio review and pricing. You can also browse other Nimbus Therapeutics alternatives we track.